Unplanned medication discontinuation as a potential pharmacovigilance signal: a nested young person cohort study

BMC Clinical Pharmacology

James Stuart McLay¹  Marion Bennie²  Peter John Helms³  Corri Black³  Bradley Kirby³  Angela Peichen Sun³ 

[1]Department of Child Health, Royal Aberdeen Children’s Hospital, Westburn Road, Aberdeen, Scotland AB25 2ZG, UK

[2]National Medicines Utilisation Unit, Information Services Division, NHS National Services Scotland, Edinburgh, Scotland

[3]Division of Applied Health Sciences, University of Aberdeen, King's College, Aberdeen AB24 3FX, UK

关键词: Young people;    Computerized;    Medical records systems;    Adverse drug reaction;    Orlistat;    Child;    Obesity;    Pharmacoepidemiology;    Pharmacovigilance;   

Others  :  860381
DOI  :  10.1186/2050-6511-15-11

 received in 2013-08-03, accepted in 2014-02-20,  发布年份 2014

【 摘 要 】

Background

Because of relatively small treatment numbers together with low adverse drug reaction (ADR) reporting rates the timely identification of ADRs affecting children and young people is problematic. The primary objective of this study was to assess the utility of unplanned medication discontinuation as a signal for possible ADRs in children and young people.

Methods

Using orlistat as an exemplar, all orlistat prescriptions issued to patients up to 18 years of age together with patient characteristics, prescription duration, co-prescribed medicines and recorded clinical (Read) codes were identified from the Primary Care Informatics Unit database between 1st Jan 2006-30th Nov 2009. Binary logistic regression was used to assess association between characteristics and discontinuation.

Results

During the study period, 79 patients were prescribed orlistat (81% female, median age 17 years). Unplanned medication discontinuation rates for orlistat were 52% and 77% at 1 and 3-months. Almost 20% of patients were co-prescribed an anti-depressant. One month unplanned medication discontinuation was significantly lower in the least deprived group (SIMD 1–2 compared to SIMD 9–10 OR 0.09 (95% CI0.01 – 0.83)) and those co-prescribed at least one other medication. At 3 months, discontinuation was higher in young people (≥17 yr versus, OR 3.07 (95% CI1.03 – 9.14)). Read codes were recorded for digestive, respiratory and urinary symptoms around the time of discontinuation for 24% of patients. Urinary retention was reported for 7.6% of patients.

Conclusions

Identification of unplanned medication discontinuation using large primary care datasets may be a useful tool for pharmacovigilance signal generation and detection of potential ADRs in children and young people.

【 授权许可】

   
2014 Sun et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Turner S, Nunn AJ, Fielding K, Choonara I: Adverse drug reactions to unlicensed and off-label drugs on paediatric wards. Acta Paediatr 1999, 88(9):965-968.
• [2]Horen B, Montastruc JL, Lapeyre-Mestre M: Adverse drug reactions and off label drug use in paediatric outpatients. Br J Clin Pharmacol 2002, 54:665-670.
• [3]Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M: Incidence of adverse drug reactions in paediatric in/out patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001, 52(1):77-83.
• [4]Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P: Adverse drug reactions in children—a systematic review. PLOS One 2012. DOI: 10.1371/journal.pone.0024061
• [5]Jonville-Bera AP, Giraudeau B, Blanc P, Beau-Salinas F, Autret-Leca E: Frequency of adverse drug reactions in children: a prospective study. Br J Clin Pharmacol 2002, 53(2):207-210.
• [6]Whyte J, Greenan E: Drug usage and adverse drug reactions in paediatric populations. Acta Paediatr Scand 1977, 66(6):767-775.
• [7]Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ: A prospective study of adverse drug reactions in hospitalised children. Br J Clin Pharmacol 1999, 47(6):681-688.
• [8]Weiss J, Krebs S, Hoffman C, Werner U, Neubert A, Brune K, Rascher W: Survey of adverse drug reactions on a paediatric ward: a strategy for early and detailed detection. Pediatrics 2002, 110(2 Pt 1):254-257.
• [9]Kramer MS, Hutchinson TA, Flegel KM, Naimark L, Contardi R, Leduc DG: Adverse drug reactions in general paediatric outpatients. J Paediatr 1985, 106(2):305-310.
• [10]Davies EC, Green CF, Mottram DR, Pirmohamed M: Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharmacol Ther 2006, 31:335-341.
• [11]Martin RM, Kapoor KV, Wilton LV, Mann RD: Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ 1998, 317:119-120.
• [12]Reporting adverse drug reactions. A guide for healthcare professionals 2006. BMA Board of Science. British Medical Association, BMA House, Tavistock Square,London, WC1H 9JP. http://www.isoponline.org/documents/news/BMAreport.pdf webcite. © British Medical Association
• [13]Smith CC, Bennet PM, Pearce HM, Harrison HI, Reynolds DJM, Aronson JK, Graeme-Smith DG: Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on the Safety of Medicines. Brit J Clin Pharmacol 1996, 42:423-9.
• [14]Schirm E, Tobil H, Van Puijenbroek EP, Monster-Simons MH, den Berg LTW DJ-v: Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharmacoepi Drug Safety 2004, 13:159-65.
• [15]Hawcutt DB, Pramod M, Riordan A, Smyth R, Pirmohamed M: Reported paediatric adverse drug reactions in the UK 2000–2009. Brit JClin Pharmacol 2012, 73:437-446. Doi: 10.1111/j.1365-2125.2011.04113.x
• [16]Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, Hazell J, Krska L, Lee AD, McLernon DJ, Murphy E, Shakir S, Watson MJ: Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme: literature review, descriptive and qualitative analyses and questionnaire surveys. Health Technol Assess 2011, 15(20):33-47.
• [17]Broyles S, Katzmarzyk PT, Srinivasan SR, Chen W, Bouchard C, Freedman DS, Berenson GS: The pediatric obesity epidemic continues unabated in Bogalusa, Louisiana. Pediatr 2010, 125(5):900-905.
• [18]Wang Y, Monteiro C, Popkin BM: Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. Am J Clin Nutr 2002, 75(6):971-977.
• [19]Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006, 26(5):968-976. 20
• [20]Must A: Morbidity and mortality associated with elevated body weight in children and adolescents. Am J Clin Nutr 1996, 63(3 Suppl):445S-447S.
• [21]Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Safety 2008, 31(1):53-65.
• [22]Acharya NV, Wilton LV, Shakir SA: Safety profile of orlistat: results of a prescription-event monitoring study. Int J Obes 2006, 30(11):1645-1652. 23: Gonzalez-Gay MA, Garcia-Porrua C, Lueiro M, Fernandez ML. Orlistat-induced cutaneous leukocytoclastic vasculitis. Arthritis & Rheumatism 2002 Oct 15;47(5):567
• [23]Sergeant A, Milne G, Shaffrali F: Lichenoid eruption associated with orlistat. Br J Dermatol 2006, 154(5):1020-1021.
• [24]McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA: Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002, 10(7):642-650.
• [25]Ozkan B, Bereket A, Turan S, Keskin S: Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004, 12(163(12)):738-741.
• [26]Norgren S, Danielsson P, Jurold R, Ltborn M, Marcus C: Orlistat treatment in obese prepubertal children: a pilot study. Acta Pædiatr 2003, 92(6):666-70.
• [27]Mohamed IN, Helms PJ, Simpson CR, Milne RM, McLay JS: Using primary care prescribing databases for pharmacovigilance. Br J Clin Pharmacol 2011, 71(2):244-249.
• [28]Mohamed IN, Helms PJ, Simpson CR, McLay JS: Using primary care prescribing databases for pharmacovigilance. Brit J Clin Pharmacol 2011, 712:244-249.
• [29]Scottish Index of Multiple Deprivation http://www.scotland.gov.uk/Topics/Statistics/SIMD webcite Accessed 01 04 2013
• [30]Read Code User Guide Dr. Lesley Graham, Ann Ward, Gerry Mulvenna. ISD Scotland July 2000 https://www.google.co.uk/search?q=Read+Code+User+Guide+Dr.+Lesley+Graham,+Ann+Ward,+Gerry+Mulvenna.+599+ISD+Scotland+July+2000.&ie=utf-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&channel=sb&gws_rd=cr&ei=SakZU8iFLaWS7AaIiYA4 webcite Accessed 23/07/2013)
• [31]Database review by PCCIU http://www.abdn.ac.uk/iahs/uploads/files/PCI.pdf webcite. Accessed 25 06 2013
• [32]Whitelaw FG, Nevin SL, Milne RM, Taylor RJ, Taylor MW, Watt AH: Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. B J G P 1996, 46(404):181-186.
• [33]Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK, 1990. Arch Dis Child 1995, 73(1):25-29.
• [34]British National Formulary, Volume No 64. BMJ and Pharmaceutical Press; 2012.
• [35]Mohamed IN, Helms PJ, Simpson CR, McLay JS: Using routinely collected prescribing data to determine drug persistence for the purpose of pharmacovigilance. J Clin Pharmacol 2011, 51(2):279-284.
• [36]Viner RM, Hsia Y, Neubert A, Wong ICK: Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study. Br J Clin Pharmacol 2009, 68(6):844-851.
• [37]Tebbi CK: Treatment compliance in childhood and adolescence. Cancer 1993, 71(10 Suppl):3441-3449.
• [38]Friedman IM, Litt IF: Adolescents’ compliance with therapeutic regimens. Psychological and social aspects and intervention. J Adolescent Health Care 1987, 8(1):52-67.
• [39]Tebbi CK, Cummings KM, Zevon MA: Compliance of pediatric and adolescent cancer patients. Cancer 1986, 58(5):1179-1184.
• [40]Tucker CM, Fennell RS, Pedersen T, Higley BP, Wallack CE, Peterson S: Associations with medication adherence among ethnically different pediatric patients with renal transplants. Pediatr Nephrol 2002, 17(4):251-256.
• [41]Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23(8):1296-1310.
• [42]Kinra S, Nelder RP, Lewendon GJ: Deprivation and childhood obesity: a cross sectional study of 20,973 children in Plymouth, United Kingdom. J Epidemiol Community Health 2000, 54(6):456-460.
• [43]Strauss RS, Knight J: Influence of the home environment on the development of obesity in children. Pediatr 1999, 103(6):e85.
• [44]Goldblatt PB, Moore ME, Stunkard AJ: Social factors in obesity. JAMA 1965, 192:1039-1044.
• [45]Sobal J, Stunkard AJ: Socioeconomic status and obesity: a review of the literature. Psychol Bull 1989, 105(2):260-275.
• [46]Yanovski JA, Krakoff J, Salaita CG, McDuffie JR, Kozlosky M, Sebring NG, Reynolds JC, Brady SM, Calis KA: Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes 2011, 60(2):477-485.
• [47]Burgert TS, Duran EJ, Goldberg-Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S: Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes 2008, 9(6):567-576.
• [48]Atabek ME, Pirgon O: Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol 2008, 21(4):339-348.
• [49]Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell CT: Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clinl Endocrinol Metab 2006, 91(6):2074-2080.
• [50]Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatr 2001, 107(4):E55.
• [51]Love-Osborne K, Sheeder J, Zeitler P: Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr 2008, 152(6):817-822.
• [52]Murray ML, de Vries CS, Wong IC: A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 2004, 89(12):1098-1102.
• [53]Zito JM, Safer DJ, Sai D, Gardner JF, Thomas D, Coombes P, Dubowski M, Mendez-Lewis M: Psychotropic medication patterns among youth in foster care. Pediatr 2008, 121(1):e157-63.
• [54]Mustillo S, Worthman C, Erkanli A, Keeler G, Angold A, Costello EJ: Obesity and psychiatric disorder: developmental trajectories. Pediatr 2003, 111(4 Pt 1):851-859.
• [55]Atlantis E, Baker M: Obesity effects on depression: systematic review of epidemiological studies. Int J Obes 2008, 32(6):881-891.
• [56]Revah-Levy A, Speranza M, Barry C, Hassler C, Gasquet I, Moro MR, Falissard B: Association between Body Mass Index and depression: the “fat and jolly” hypothesis for adolescents girls. BMC Public Health 2011, 11:649. BioMed Central Full Text
• [57]Chanoine J, Hampl S, Jensen C, Boldrin M, Hauptman J: Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005, 293(23):2873-83.
• [58]Singh A, Sarkar SR, Gaber LW, Perazella MA: Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007, 49(1):153-157.
• [59]Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, Wald R, Amit MPH, Garg X: Orlistat and acute kidney injury: an analysis of 953 patients. Arch Intern Med 2011, 171(7):703-4.
• [60]MHRA orlistat drug analysis print http://www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/YellowCarddata/Druganalysisprints/index.htm?secLevelIndexChar=Oq%20-%20Ou#retainDisplay webcite Accessed 22.01.2014
• [61]Highlights of prescribing information-Xenical http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf webcite Accessed 19/06/2013)
• [62]The World Health Organisation: Pharmacovigilance toolkit. pharmacovigilance methods. http://www.pvtoolkit.org/index.php?option=com_content&view=article&id=6&Itemid=10 webcite Accessed 20. 07 2013